Clinical Trials in Baltimore

Showing 6921-6940 of 23,476 trials

A First in Human Study of CMND-100 in Healthy and Alcohol Use Disorder (AUD) Subjects

NCT05913752

The primary objective of this study is to find the tolerable dose and characterize the safety and pharmacokinetics/ pharmacodynamics (PK/PD) of single and repeated dose of CMND-100 in Healthy Volunteers (HV) and Subjects with Binge Drinking/Alcohol Use Disorder (AUD). The secondary objective of this study is to preliminarily evaluate the efficacy of CMND-100 in reduction of drinking patterns and craving in subjects with binge drinking or/and moderate to severe AUD.

Alcohol Use Disorder

Clearmind Medicine Inc.84 participantsStarted Mar 2025

New Haven, Connecticut, United States • Baltimore, Maryland, United States • Ramat Gan, Israel

COMPLETED< 1 mile

COVID-19 Vaccine Response in Sickle Cell Disease

NCT05139992

The purpose of this study is to assess the antibody response to COVID-19 vaccination in a cohort of patients with sickle cell disease (SCD) and to assess vaccine and SCD related complications around the time of vaccination.

Sickle Cell DiseaseCOVID-19

ASH Research Collaborative59 participantsStarted Dec 2021

Oakland, California, United States • Washington D.C., District of Columbia, United States • Baltimore, Maryland, United States +5 more locations

A First in Human Study of CMND-100 in Healthy and Alcohol Use Disorder (AUD) Subjects

COVID-19 Vaccine Response in Sickle Cell Disease

Find Trials by Condition in Baltimore

Tamoxifen in Women With Breast Cancer and in Women at High-Risk of Breast Cancer Who Are Receiving Venlafaxine, Citalopram, Escitalopram, Gabapentin, or Sertraline

STOP Persistent AF

Pulsed Field Ablation to Irreversibly Electroporate Tissue and Treat AF

Study Assessing the Efficacy and Safety of Alpelisib Plus Fulvestrant in Men and Postmenopausal Women With Advanced Breast Cancer Which Progressed on or After Aromatase Inhibitor Treatment.

Radiation Therapy With or Without Chemotherapy in Treating Patients With High-Risk Malignant Salivary Gland Tumors That Have Been Removed By Surgery

Study of RS1 Ocular Gene Transfer for X-linked Retinoschisis

Advancing Feasibility and Acceptability of Digital Cognitive Rehabilitation in Sickle Cell Disease

A Study Evaluating Safety and Tolerability, and Pharmacokinetics of Navitoclax Monotherapy and in Combination With Ruxolitinib in Participants With Myeloproliferative Neoplasm

Evaluation of Lasofoxifene Combined With Abemaciclib in Advanced or Metastatic ER+/HER2- Breast Cancer With an ESR1 Mutation

Alcoholic Hepatitis Network Observational Study

Evaluate the Safety, Tolerability, Pharmacodynamics and Efficacy of CNP-106 in Subjects With Myasthenia Gravis

Trametinib in Treating Patients With Advanced Cancer With or Without Hepatic Dysfunction

IO-202 as Monotherapy and IO-202 Plus Azacitidine ± Venetoclax in Patients in AML and CMML

TAC T-cells for the Treatment of Claudin 18.2 Positive Solid Tumors (TACTIC-3)

Myeloma-Developing Regimens Using Genomics (MyDRUG)

Evaluation of Brimonidine Tartrate/Ketotifen Fumarate Combination for the Treatment of Allergic Conjunctivitis

Study of the Efficacy of Lurasidone in Cognitive Functioning in Bipolar Patients

A Study of Lumasiran in Infants and Young Children With Primary Hyperoxaluria Type 1